Centogene Past Earnings Performance
Past criteria checks 0/6
Centogene's earnings have been declining at an average annual rate of -25.2%, while the Healthcare industry saw earnings growing at 7% annually. Revenues have been growing at an average rate of 6.1% per year.
Key information
-25.2%
Earnings growth rate
47.7%
EPS growth rate
Healthcare Industry Growth | 8.5% |
Revenue growth rate | 6.1% |
Return on equity | n/a |
Net Margin | -79.1% |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Centogene N.V.'s (NASDAQ:CNTG) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors
Feb 16Centogene N.V. (NASDAQ:CNTG) Might Not Be As Mispriced As It Looks
Dec 21Centogene GAAP EPS of -€0.28, revenue of €10.32M
Jul 15Is Centogene (NASDAQ:CNTG) Using Debt In A Risky Way?
Nov 25Is Centogene (NASDAQ:CNTG) Using Debt Sensibly?
Jun 29Centogene reports Q1 results
Jun 16Centogene, Alector initiate EFRONT study in frontotemporal dementia
Jun 02Centogene to nominate Rene Just as CFO at the upcoming Annual General Meeting
May 26Need To Know: Analysts Are Much More Bullish On Centogene N.V. (NASDAQ:CNTG)
Apr 17What Percentage Of Centogene N.V. (NASDAQ:CNTG) Shares Do Insiders Own?
Mar 05Update: Centogene (NASDAQ:CNTG) Stock Gained 11% In The Last Year
Jan 29Is Centogene (NASDAQ:CNTG) A Risky Investment?
Dec 18Centogene reports Q3 results
Dec 16Centogene and Alnylam launch a clinical screening program targeting rare hereditary disease
Dec 08Centogene expands partnership with PTC Therapeutics in rare genetic disorder
Nov 25Revenue & Expenses BreakdownBeta
How Centogene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 51 | -40 | 45 | 15 |
31 Mar 23 | 49 | -40 | 44 | 16 |
31 Dec 22 | 47 | -39 | 42 | 17 |
30 Sep 22 | -15 | -44 | 46 | 20 |
30 Jun 22 | 2 | -58 | 49 | 20 |
31 Mar 22 | 190 | -44 | 55 | 20 |
31 Dec 21 | 42 | -57 | 54 | 19 |
30 Sep 21 | 162 | -40 | 59 | 17 |
30 Jun 21 | 168 | -24 | 57 | 18 |
31 Mar 21 | 126 | -27 | 55 | 17 |
01 Jan 21 | 38 | -60 | 49 | 15 |
30 Sep 20 | 73 | -30 | 43 | 14 |
30 Jun 20 | 49 | -28 | 39 | 11 |
31 Mar 20 | 50 | -24 | 35 | 11 |
31 Dec 19 | 49 | -21 | 33 | 10 |
30 Sep 19 | 44 | -19 | 30 | 9 |
30 Jun 19 | 45 | -16 | 30 | 8 |
31 Mar 19 | 43 | -13 | 28 | 7 |
31 Dec 18 | 40 | -11 | 26 | 6 |
30 Sep 18 | 39 | -9 | 23 | 7 |
31 Dec 17 | 32 | -5 | 15 | 6 |
31 Dec 16 | 28 | -5 | 14 | 6 |
Quality Earnings: CNTG is currently unprofitable.
Growing Profit Margin: CNTG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CNTG is unprofitable, and losses have increased over the past 5 years at a rate of 25.2% per year.
Accelerating Growth: Unable to compare CNTG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CNTG is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (9.2%).
Return on Equity
High ROE: CNTG's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.